Clinical trial
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic…
NCT00132015 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00132015 |
|---|---|
| Title | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis |
| Official title | A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Nonneoplastic Condition, Precancerous Condition |
| Intervention type | Drug |
| Interventions | tanespimycin |
| Enrollment | 37 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Aug 19, 2005 |
| Last update posted | Mar 15, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: